Featured Partners

Abbott Announces Start of Study to Evaluate New Device to Treat Recurrent Atrial Fibrillation

Originally published on Abbott.com – Recurrent irregular heartbeat–also known as atrial fibrillation–impacts more than 16 million people globally – Trial supports Abbott’s focus on being the best partner for electrophysiologists treating people living with atrial fibrillation Abbott announced first enrollments in the TactiFlex PAF IDE study to evaluate a new…

Sanofi Discusses The Impact of COVID-19 on Cancer

Originally published on sanofi.com. The havoc caused by the COVID-19 pandemic continues to disrupt daily life, but its reach goes deeper and further with mounting consequences for cancer patients who need ongoing treatment. Hospitals and clinics have shifted daily resources to cope with an influx of patients with COVID-19 disease,…

The Future of Sustainable Packaging: Dow introduces INNATE™ TF Polyethylene Resins for Tenter Frame Biaxial Orientation

Originally published on Dow.com Answering the industry needs of high performance, consumer convenience, and recyclability, Dow is excited to announce an innovative and revolutionary brand extension to the family of INNATE™ Precision Packaging Resins. INNATE™ TF Polyethylene Resins for Tenter Frame Biaxial Orientation are bringing commercial viability to a long-desired packaging goal:…

johnson and johnson

Janssen Announces U.S. FDA Approval of SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for SPRAVATO® (esketamine) CIII nasal spray, taken with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation orbehavior.1SPRAVATO® is the first and only approved medicine that has been shown to reduce depressive symptoms within 24 hours,1 providing a new option for significant symptom relief until a longer-term, comprehensive treatment plan can take effect.

AT&T: Leading with Listening and Four Key Pillars Supporting Transformation – People, Process, Technology and Culture

Originally published on ATT.com The first blog in the series discussed how companies need to invest in creating Transformational DNA. The second blog defined the five characteristics of Transformational DNA. At its core, any service organization must embody humility. This means leading with listening. It’s been critical to ensuring adoption across our organization. As…

johnson and johnson

Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine

Johnson & Johnson (NYSE: JNJ) (the Company) today announced its Janssen Pharmaceutical Companies have entered into an agreement with the U.S. government for the large scale domestic manufacturing and delivery in the U.S. of 100 million doses of Janssen’s SARS-CoV-2 investigational vaccine, Ad26.COV2.S, for use in the United States following approval or Emergency Use Authorization by the U.S. Food and Drug Administration (FDA).